文献速递主动脉疾病

腹主动脉瘤血管内修复的Medicare费用:VQI分析

Medicare costs for endovascular abdominal aortic aneurysm treatment in the Vascular Quality Initiative.
PubMed 文献 · J Vasc Surg · 2020-07-15

基于VQI-Medicare链接数据,1207例腹主动脉瘤血管内修复患者随访5年,5年再干预率18%。首次EVR住院中位费用25,745美元,再干预中位费用22,165美元,每次再干预费用与初次手术相当。

要点

  • EVR后5年再干预率为18%,多数再干预患者仅需一次再干预。
  • 首次EVR住院中位费用25,745美元,再干预中位费用22,165美元。
  • 多次再干预使累积费用阶梯式上升,每次再干预费用与初次EVR相近。

核心结论

  • Medicare为EVR后每次再干预支付的费用与初次手术大致相同,三次再干预的个体累计费用可超过100,000美元。

研究设计与样本

  • 研究纳入Vascular Quality Initiative中接受EVR并链接Medicare索赔文件的患者,最终分析队列为1207例,随访至死亡或5年。

主要发现

  • 1207例患者平均年龄76.2岁(±7.1岁),女性占21.6%,91.1%的手术为择期。
  • 5年Kaplan-Meier再干预率为18%。
  • 再干预患者中,154例(73.7%)接受一次再干预,40例(19.1%)接受两次,15例(7.2%)接受三次或以上。
  • 首次EVR住院中位费用为25,745美元(IQR 21,131-28,774美元),再干预中位费用为22,165美元(IQR 17,152-29,605美元)。
  • 多次再干预患者的累积费用呈阶梯式增加,每次再干预费用与首次EVR相似。

临床怎么用

  • 外科医生、患者和医疗系统需考虑EVR的长期财务影响,累积费用可能影响EVR优先治疗策略的财务可行性。
  • 应审慎选择患者以平衡EVR的长期费用与获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Reintervention after endovascular repair (EVR) of abdominal aortic aneurysms is common. However, the cumulative financial impact of reintervention after EVR on a national scale is poorly defined. Our objective was to describe the cost to Medicare for aneurysm treatment (EVR plus reinterventions) among a cohort of patients with known follow-up for 5 years after repair. METHODS: We identified patients who underwent EVR within the Vascular Quality Initiative who were linked to their respective Medicare claims file (n = 13,995). We excluded patients who underwent EVR after September 30, 2010, and those who had incomplete Medicare coverage (n = 12,788). The remaining cohort (n = 1207) had complete follow-up until death or 5 years (Medicare data available through September 30, 2015). We then obtained and compiled the corresponding Medicare reimbursement data for the index EVR hospitalization and all subsequent reinterventions. RESULTS: We studied 1207 Medicare patients who underwent EVR and had known follow-up for reinterventions for 5 years. The mean age was 76.2 years (±7.1 years), 21.6% of patients were female, and 91.1% of procedures were elective. The Kaplan-Meier reintervention rate at 5 years was 18%. Among patients who underwent reintervention, 154 (73.7%) had a single reintervention, 40 (19.1%) had two reinterventions, and 15 (7.2%) had three or more reinterventions. The median cost to Medicare for the index EVR hospitalization was $25,745 (interquartile range, $21,131-$28,774). The median cost for subsequent reinterventions was $22,165 (interquartile range, $17,152-$29,605). The cumulative cost to Medicare of aneurysm treatment (EVR plus reinterventions) increased in a stepwise fashion among patients who underwent multiple reinterventions, with each reintervention being similar in cost to the index EVR. CONCLUSIONS: The overall cost incurred by Medicare to reimburse for each reintervention after EVR is roughly the same as for the initial procedure itself, meaning that Medicare cost projections would be greater than $100,000 for any individual who undergoes an EVR with three reinterventions. The long-term financial impact of EVR must be considered by surgeons, patients, and healthcare systems alike as these cumulative costs may hinder the fiscal viability of an EVR-first therapeutic approach and highlight the need for judicious patient selection paradigms.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Columbo JA, Goodney PP, Gladders BH, et al. Medicare costs for endovascular abdominal aortic aneurysm treatment in the Vascular Quality Initiative. J Vasc Surg. 2020. PMID: 32682064. doi:10.1016/j.jvs.2020.06.109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。